Chronic Liver Disease Market

Key Highlights of the Report:

• The chronic Liver Disease Market is likely to observe a transformation due to increasing prevalence, improved diagnostic techniques, and changes in the treatment landscape, including advancements in the therapeutic portfolio.
• The treatment goal in Chronic Liver Disease is to stop the progression of the disease and complications where the principle of management is mainly underlying cause correction, portal hypertension management, and specific treatments for individual diseases. Chronic liver disease is burdensome as it lacks effective approved pharmacological therapies.
• The lack of drug approvals by authorized organizations hinders pharmaceutical market growth. Organ transplant is reserved for end stage liver disease patients and is quickly becoming a sizeable market in itself. 
• There is some optimism that new medications are likely to emerge during the forecast period. Semaglutide by Gilead Sciences, Inc. and Novo Nordisk A/S, Madrigal lead candidate, Resmetirom (formerly MGL-3196), along with various early and mid-staged clinical staged developmental candidates are currently shaping up the therapeutic landscape of Chronic Liver Disease addressing a vast array of unmet needs including combatting the underlying etiologies as well as complications associated.  

DelveInsight’s “Chronic Liver Disease – Market Insights, Epidemiology, and Market Forecast – 2032” comprehensively analyzes the Chronic Liver Disease market, including market insights, market forecasts, drug uptakes, and drug penetration.

The report examines historical epidemiology data for diagnosed prevalent cases and projects the same for the forecast period. Chronic Liver Disease diagnosed cases are further segmented by severity and treatable cases. The report also offers an in-depth understanding of various aspects of the disease, including diagnosis algorithm, prescription patterns, physician perceptions on treatment, current and future market developments for the 7MM, including the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2019 to 2032.

We provide country-wise in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of the pipeline products supporting the clients in their decision-making process regarding their therapeutic portfolio.

In order to gauge the market’s overall potential and recognize business opportunities, the report discusses the existing Chronic Liver Disease treatment practices and highlights unmet medical needs. 

Chronic Liver Disease Diagnosis and Treatment Algorithm 

The diagnosis of Chronic Liver Disease depends upon the etiology and complications of the disease. As mentioned, a key challenge is that a liver biopsy can confirm the diagnosis of Chronic Liver Disease, which is invasive. Some other diseases may mimic the presentation of Chronic Liver Disease, making differential diagnosis necessary. Concerning the above, the absence of a treatment portfolio indicates diagnostic loopholes.

In the absence of any existing FDA-approved medications for the treatment of NAFLD/NASH, the mainstay of management continues to be dietary and other lifestyle changes tailored to the individual patient. The current treatments for this illness are not keeping up with advances in medical research and technology. Discovering novel and effective medicines that address the intricacies of chronic liver disease and improve patient outcomes is critical. The management of this illness can be improvised to better the quality of life for those living with chronic liver disease by embracing innovative treatment methods. Numerous medications have been added to the pipeline of novel therapies, increasing the promise of successful treatment of NASH. In the meantime, first-line drugs such as vitamin E and pioglitazone continue to serve their purpose in carefully selected patients, with or without diabetes.

Bearing in mind the characteristics discussed, it is the need of the hour to introduce diagnostic procedures that are gold standard non-invasively along with the forecast period treatment approvals as multiple drugs in the hepatology space have already entered the “Hepatology graveyard” accrediting to after failed studies. 

Chronic Liver Disease Epidemiology 

This section provides a glimpse of the Chronic Liver Disease epidemiology in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

The Chronic Liver Disease Epidemiology section provides insights into historical, current, and forecasted trends of the Chronic Liver Disease patient pool segmented by age, gender, and risk factors. This part of the report also provides the diagnosed and treated patient pools, their trends, and assumptions undertaken.

Key Findings

According to Ginès et al. (2016), the prevalence of increased liver stiffness in the general adult population without previously known liver diseases is high (between 5.6% and 7.5%). The prevalence among individuals with risk factors is much higher (between 18% and 27%), which suggests an alarmingly high prevalence of chronic liver diseases in the general population.

According to Axley et al. (2018), the fibrosis stages range from F0 to F4. Advanced liver fibrosis is an important predictor of liver disease progression and mortality, and current guidelines recommend screening for complications of cirrhosis once patients develop F3 fibrosis. 

According to Ginès et al. (2016), studies have shown that 6–7% of adults without known liver disease have liver fibrosis, mostly associated with non-alcoholic fatty liver disease. 

Chronic Liver Disease Market Outlook

The management of patients with Chronic Liver Disease depends on the stage of the liver disease. Liver fibrosis and cirrhosis result from underlying conditions like NASH, ALD, CHB, CHC, and others which progress to a stage of severity that becomes chronic due to the lack of standard treatment. 

As per the guidelines from the American Liver Foundation, without any branded approvals, management of underlying comorbidity that is central to treating NASH and related fibrosis is of utmost importance. Various off-label therapies are used to manage Chronic Liver Disease complications, such as vitamin E (an antioxidant), insulin sensitizers (e.g., metformin, pioglitazone), anti-hyperlipidemic agents (e.g., gemfibrozil), pentoxifylline, and UDCA. 

According to DelveInsight, the Chronic Liver Disease market is expected to witness considerable changes in the 7MM during the study period 2019–2032.

Chronic Liver Disease Drug Chapters 

Emerging Drugs

While several late-staged and early-staged therapeutics are under development, the pharmaceutical product pipeline of Chronic Liver Disease is prolific. It includes leading pharma players in the pursuit of cracking the code in the protracted hepatology space.

Semaglutide: Novo Nordisk 

Semaglutide is a selective GLP-1 receptor agonist given once daily, subcutaneously, for the treatment of non-alcoholic steatohepatitis (NASH). Based on studies, the development of Semaglutide in NASH is very much on track. It is currently in Phase III of its clinical development with a promise for closer to a solution that can be a potential launch in the hepatology space during the forecast period. 

Resmetirom (formerly MGL-3196): Madrigal Pharmaceuticals

Madrigal’s main attraction was its lead NASH compound, MGL-3196, a once-daily pill for fatty liver disease in-licensed from Roche, Resmetirom (formerly MGL-3196), a Phase III molecule that is a first-in-class, oral, once-daily formulation to target F2 and F3, and F4 stage patients. The company plans to file subpart H-accelerated approval for sooner entry into the market. This filling will be done based on recently published results; later, it will be continued by full NDA submission. Resmetirom also has FTD, which will help shorten the filling period. If all goes as planned, Resmetirom can be a potential launch in the hepatology space during the forecast period.

Note: Detailed emerging therapies assessment will be provided in the final report.

Chronic Liver Disease Market Segmentation

The DelveInsight report provides a detailed outlook of the current and future market of Chronic Liver Disease, segmented by countries, by therapies, and by classes to emphasize the changing market dynamics during the forecast period. 

Market Size by Countries

The total market of Chronic Liver Disease is analyzed for individual countries (the United States Market, EU4 (Germany, France, Italy, and Spain) and the UK market, and Japan Market). Due to a high number of prevalent cases and higher cost of therapies, the United States captured a higher share of the Chronic Liver Disease market in 2022 and is expected to continue to dominate the Chronic Liver Disease market in the future with plausible early entries of emerging products.

Market Size by Therapies

The total market, historical and forecast, is segmented by therapies and drug classes. In the case of Chronic Liver Disease, the market consists of non-surgical treatments, medications, and surgical interventions. The diagnosis of Chronic Liver Disease depends upon the etiology and complications of the disease, wherein a liver biopsy can confirm the diagnosis of Chronic Liver Disease. In most Chronic Liver Disease patients, “etiologic therapy” aims to eliminate the disease’s causal agents. However, despite etiologic therapies, some patients with decompensated cirrhosis are at risk of additional disease development. Therefore, novel therapeutics are urgently needed to focus on critical stages in the intricate pathophysiological chain of decompensated cirrhosis. Pertaining to the above-mentioned, culminating to all the factors has led to greater interest by key pharmaceutical players such as Novo Nordisk A/S, Madrigal Pharmaceuticals, Axcella Therapeutics, 89bio, Inc., and others to develop newer therapies that can drive the treatment market in the future.

Chronic Liver Disease Drugs Uptake

This section focuses on the sales uptake of potential drugs anticipated to be launched in the Chronic Liver Disease market between 2023 and 2032. It estimates the market penetration of the drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the market. 

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Chronic Liver Disease.

Chronic Liver Disease Market Access and Reimbursement

DelveInsight’s Chronic Liver Disease Market report provides a descriptive overview of the market access and reimbursement scenario of Chronic Liver Disease.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, illuminating the market access, reimbursement policies, and health technology assessments. 

KOL Views

To keep up with current market trends and fulfill gaps in secondary findings, we conduct interviews with KOLs and SMEs’ working in the Chronic Liver Disease domain. Their opinions understand and validate current and emerging treatment patterns or Chronic Liver Disease market trends. This will support the clients with potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs. 

Chronic Liver Disease: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, hospitals, etc., such as Chronic Liver Disease Foundation, American Liver Foundation, and others.

E.g., “People who stop drinking alcohol after being diagnosed with a problem see significant improvement within 6–12 months.”

“Out of problem drinkers, around 35% experience severe liver disease due to various factors that worsen, delay, or stop the progression of alcoholic liver disease.”

Note: Detailed assessment of KOLs Views will be provided in the full report on Chronic Liver Disease.

Chronic Liver Disease Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Chronic Liver Disease Market using various Competitive Intelligence tools, including SWOT analysis, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Chronic Liver Disease Pipeline Development Activities

The report covers detailed information on collaborations, acquisition and merger, licensing, patent details, and other information for Chronic Liver Disease emerging therapies.

Chronic Liver Disease Report Insights

• Patient Population
• Therapeutic Approaches
• Chronic Liver Disease Pipeline Analysis
• Chronic Liver Disease Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Chronic Liver Disease Report Key Strengths

• Chronic Liver Disease 10 Years Market Forecast
• The 7MM Coverage
• Chronic Liver Disease Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Chronic Liver Disease Drugs Uptake

Chronic Liver Disease Report Assessment

• Chronic Liver Disease Current Treatment Practices
• Unmet Needs
• Chronic Liver Disease Pipeline Product Profiles
• Chronic Liver Disease Market Attractiveness

Key Questions

• What are the major key players in the Chronic Liver Disease treatment space?
• At what CAGR is the Chronic Liver Disease market expected to grow by 7MM during the forecast period (2023–2032)?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
• What are the disease risk, burden, and regional/ethnic differences of Chronic Liver Disease?
• Where will be the growth opportunities in the 7MM concerning the patient population with Chronic Liver Disease? 
• What are the current treatment guidelines for treating Chronic Liver Disease in the US, Europe, and Japan?
• What major factors drive the market growth in the Chronic Liver Disease space?
• What are the current challenges faced in drug development?